The logo represented product uniformity ... The final collaboration in 2008 was with San Francisco-based Exelixis to develop and commercialize two novel therapies: one for medullary thyroid ...

Bank of America Securities analyst Jason Gerberry maintained a Hold rating on Exelixis (EXEL – Research Report) today and set a price target of ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report). The ...

It has been about a month since the last earnings report for Exelixis (EXEL). Shares have added about 13.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

During the last three months, 25 analysts shared their evaluations of Exelixis (NASDAQ:EXEL), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ratings ...

In recent trading, shares of Exelixis Inc (Symbol: EXEL) have crossed above the average analyst 12-month target price of $37.05, changing hands for $37.18/share. When a stock reaches the target an ...

Exelixis relies heavily on cabozantinib, with potential growth from its NETs approval, but faces patent expiration (after 2030). Zanzalintinib shows promise in ongoing trials but lacks definitive ...

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Over the last 7 days, the United States market has experienced a 2.5% ...

Exelixis gained an exclusive option to license XB002 (then ICON-2) in exchange for an upfront payment to Iconic of $7.5 million and a commitment of preclinical development funding.